Twitter Beğeni Hilesi

GRAIL in the NHS. politically driven and unlikely to benefit patients. bmj.com/content/386/bm… thanks to Richard Sullivan Clare Turnbull- Prof/NHS Dr Paul Pharoah (R soul) 🇪🇺🇵🇬🇿🇦🇬🇧 and the many anon people who spoke to us. David Cameron Nadhim Zahawi

Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint inhibition therapy. ja.ma/4cyQmwN

18 anti-cancer drugs approved in the neo/adjuvant setting since 2018. With Vinay Prasad MD MPH & Alyson Haslam, we R keeping a close eye on those. update data with AEGEAN: timotheeolivier-research.com/neo-adjuvant-t… 7 just in lung cancer !👇 Alfredo Addeo MD Solange Peters H. Jack West, MD, FASCO Patrick Forde LARVOL

Our paper is out on the regulatory history of Ibrutinib

New commentary by Timothée Olivier, MD et al reviews the history of HER2 in sarcoma and explore the role of TDXd as a treatment for patients with sarcomas. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… OncoAlert #sarcoma

Tissue agnostic approvals from 2017 till now ESMO - Eur. Oncology . Lets see the Other side of the coin. 1 - It is great to have Tissue Agnostic approvals and works well for NTRK fusion, B-RAF mutation and RET fusion and to some extent for MSI high . But for HER2-3 plus and TMB high

Happy to have my friend and colleague Brian Schulte from UC San Francisco cover our recent paper on drugdevletter.com Check it out: 👇 drugdevletter.com/p/fda-agnostic… + subscribe to the "drug dev letter" to get more content!

Systematic review found that 43% of randomized clinical trials of anticancer treatment in the adjuvant or neoadjuvant context failed to present any assessable postrecurrence treatment data. ja.ma/3YMKZGH

Some thoughts on #ESCCongress decision to remove women from CHADS-2-VASc. drvinayprasad.com/p/women-have-m…

Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma? Quality-of-Life, Non-Inferiority, and Duration of Treatment in RATIONALE-301. Quality-of-life data should be interpreted with extra caution when censoring rates are high open.substack.com/pub/developdru… via Timothée Olivier, MD

Check out our EJC perspective here on the subject of CDK4/6 inhibitors as adjuvant therapies in breast cancer 👇VKPrasadLab sciencedirect.com/science/articl…

Check out the cover in the drugdevletter.com of our recently published work in EJC w/ Alyson Haslam and Vinay Prasad MD MPH Tislelizumab, a novel anti-PD1 in hepatocellular carcinoma ? (tweetorial here : x.com/Timothee_MD/st…) Cover here 👇 drugdevletter.com/p/tislelizumab…

Great to see Dr. Alfredo Addeo MD discuss EGFR PACC mutations at #WCLC24